Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615007 | 0.92 | MRGPRX4 (0.37) | CNR2ESR1ESR2HTR1AHTR1D | |
| SCHEMBL617022 | 0.81 | TTR (0.45) | CNR2SLC22A12MRGPRX4 | |
| SCHEMBL16494467 | 0.78 | SLC22A12 (0.36) | CNR2ESR1ESR2SLC22A12EGLN2 | |
| SCHEMBL618435 | 0.77 | ALDH1A1 (0.40) | NPC1RAB9ATYK2 | |
| SCHEMBL13032387 | 0.76 | TRPV4 (0.46) | CNR2SLC22A12 | |
| SCHEMBL16496916 | 0.73 | ESR1 (0.37) | ESR1ESR2RAB9A | |
| SCHEMBL615006 | 0.73 | MRGPRX4 (0.46) | MRGPRX4 | |
| SCHEMBL10064303 | 0.73 | LMNA (0.45) | RAB9AMRGPRX4AR | |
| SCHEMBL16494944 | 0.72 | KDM4E (0.38) | ESR1ESR2 | |
| SCHEMBL615319 | 0.72 | HTR5A (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2394988-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | CNR2 476/4885ESR1 1541/4885ESR2 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.